×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Clinical: PMN310 Anti-Amyloid for AD (NCT06750432)
clinical
4,244 words
KG: PMN310 Anti-Amyloid for AD (NCT06750432)
Contents
PMN310 Anti-Amyloid for AD (NCT06750432)
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (46)
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
TREM2-Dependent Microglial Senescence Transition
Score: 0.54
Lysosomal Membrane Repair Enhancement
Score: 0.54
← Prev
pg 3/3
Related Analyses (20)
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Show 15 more
Related Experiments (15)
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Show 10 more
Knowledge Graph (2 edges)
PMN310 Anti-Amyloid for AD (NCT06750432)
references
BACE1
PMN310 Anti-Amyloid for AD (NCT06750432)
references
GFAP
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)